Skip to main content
. 2021 Jan 12;10(1):144. doi: 10.3390/cells10010144

Figure 1.

Figure 1

CDK8/19 inhibitors senexin B (SNXB) and 15w prevent resistance to EGFR inhibitors gefitinib (GEF) and erlotinib (ERLO) in BT474 breast cancer cells. (A). Representative photographs of crystal violet-stained flasks at 2, 4, and 8 weeks of treatment. (B). Representative phase-contrast microphotographs at 3 days, and at 1, 2, 3, 4 and 8 weeks of treatment. (C). Densitometric measurements of microphotographs expressed as percentage of cell density in DMSO controls at 3 weeks. Data shown as mean (n = 4 images/flask) ± SEM. p < 0.0001 for GEF vs. GEF+SNXB/15w (*) and ERLO vs. ERLO+SNXB/15w (*) at 8 weeks.